JP2023516745A5 - - Google Patents

Info

Publication number
JP2023516745A5
JP2023516745A5 JP2022553181A JP2022553181A JP2023516745A5 JP 2023516745 A5 JP2023516745 A5 JP 2023516745A5 JP 2022553181 A JP2022553181 A JP 2022553181A JP 2022553181 A JP2022553181 A JP 2022553181A JP 2023516745 A5 JP2023516745 A5 JP 2023516745A5
Authority
JP
Japan
Prior art keywords
weeks
approximately
pharmaceutical composition
administered
lsd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022553181A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023516745A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/021101 external-priority patent/WO2021178807A1/en
Publication of JP2023516745A publication Critical patent/JP2023516745A/ja
Publication of JP2023516745A5 publication Critical patent/JP2023516745A5/ja
Pending legal-status Critical Current

Links

JP2022553181A 2020-03-06 2021-03-05 小細胞肺癌および/または扁平上皮非小細胞肺癌の処置方法 Pending JP2023516745A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062986541P 2020-03-06 2020-03-06
US62/986,541 2020-03-06
PCT/US2021/021101 WO2021178807A1 (en) 2020-03-06 2021-03-05 Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc

Publications (2)

Publication Number Publication Date
JP2023516745A JP2023516745A (ja) 2023-04-20
JP2023516745A5 true JP2023516745A5 (cg-RX-API-DMAC7.html) 2024-03-06

Family

ID=77614361

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022553181A Pending JP2023516745A (ja) 2020-03-06 2021-03-05 小細胞肺癌および/または扁平上皮非小細胞肺癌の処置方法

Country Status (11)

Country Link
US (1) US20230089536A1 (cg-RX-API-DMAC7.html)
EP (1) EP4114398A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023516745A (cg-RX-API-DMAC7.html)
KR (1) KR20220151637A (cg-RX-API-DMAC7.html)
CN (1) CN115484958A (cg-RX-API-DMAC7.html)
AU (1) AU2021230575A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022017637A2 (cg-RX-API-DMAC7.html)
CA (1) CA3170456A1 (cg-RX-API-DMAC7.html)
IL (1) IL296564A (cg-RX-API-DMAC7.html)
MX (1) MX2022010912A (cg-RX-API-DMAC7.html)
WO (1) WO2021178807A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018276611B2 (en) 2017-05-31 2022-01-06 Taiho Pharmaceutical Co., Ltd. Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1
MX2022005811A (es) 2019-11-13 2022-06-08 Taiho Pharmaceutical Co Ltd Sal novedosa de compuesto de terfenilo.
TW202329934A (zh) * 2021-09-30 2023-08-01 日商大鵬藥品工業股份有限公司 使用聯苯化合物及免疫檢查點分子調節劑之用於癌症的組合療法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
CA3175360C (en) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
WO2015168466A1 (en) 2014-05-01 2015-11-05 Quanticel Pharmaceuticals, Inc. Inhibitors of lysine specific demethylase-1
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
PE20231958A1 (es) 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗pd−1抗体及びその使用方法
EP3402255B1 (en) 2016-02-02 2021-03-31 Huawei Technologies Co., Ltd. Emission power verification method, user equipment, and base station
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2019075327A1 (en) * 2017-10-12 2019-04-18 Dana-Farber Cancer Institute, Inc. TREATMENT OF MERKEL CELL CARCINOMA
US11685782B2 (en) * 2017-10-23 2023-06-27 Children's Medical Center Corporation Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy
AU2018377852B2 (en) * 2017-11-29 2022-03-24 Epiaxis Therapeutics Pty Ltd Enhancing T-cell function and treating a T-cell dysfunctional disorder with a combination of an LSD inhibitor and a PD1 binding antagonist
CA3143030A1 (en) * 2019-06-13 2020-12-17 Celgene Corporation Methods of treating cancer by targeting cold tumors

Similar Documents

Publication Publication Date Title
Van Elslande et al. Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection
Petrone et al. In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy
Icenogle COVID-19: infection or autoimmunity
Farroni et al. Kinetics of the B-and T-cell immune responses after 6 months from SARS-CoV-2 mRNA vaccination in patients with rheumatoid arthritis
JP2022536412A5 (cg-RX-API-DMAC7.html)
Woolsey et al. Immune correlates of postexposure vaccine protection against Marburg virus
Miyazaki et al. Corneal endothelial cells activate innate and acquired arm of anti-viral responses after cytomegalovirus infection
Luka et al. Molecular characterization of peste des petits ruminants virus from the Karamoja region of Uganda (2007-2008)
Aloisi et al. MINI-review of Epstein-Barr virus involvement in multiple sclerosis etiology and pathogenesis
US20220257657A1 (en) Manipulation and use of antigen-specific regulatory t cells
An et al. Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patients
CA3170456A1 (en) Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc
JP2024539370A5 (cg-RX-API-DMAC7.html)
Zhou et al. Comparing TCR beta chain variable gene profile skewness between children with tuberculosis and BCG-vaccinated children
US20250147046A1 (en) New method for identifying herv-derived epitopes
Hagihara et al. Clinical efficacy of imdevimab/casirivimab for persistent Omicron SARS-CoV-2 infection in patients with hematological malignancies
Nogimori et al. mRNA vaccine induces cytotoxic CD8+ T-cell cross-reactivity against SARS-CoV-2 Omicron variant and regulates COVID-19 severity
Bellanger et al. Fungal peptides from pneumonitis hypersensitivity etiologic agents are able to induce specific cellular immune response
US20260036592A1 (en) DETECTION OF ANTI-VIRAL CDR3s IN CANCER
Bartholomeus et al. Transcriptomic profiling of different responder types in adults after a Priorix® vaccination
Drennan et al. Immunogenicity of MVA-BN vaccine deployed as mpox prophylaxis: a prospective cohort study and analysis of transcriptomic predictors of response
mM Supplementary Figure
ASSAID et al. COVID-19: The immune responses and immunotherapy
Smith Impact of Advanced Age and Dietary Energy Balance on Mammary Tumor Progression and the Tumor Microenvironment
Green et al. Epstein-Barr Virus and Posttransplant Lymphoproliferative Disorder